Oncotarget

Withdrawal Notice

This paper was originally published in Oncotarget Advance Online Publications on 08/10/2019.
In compliance with Oncotarget's withdrawal policy, the paper was withdrawn in its entirety. It will not appear in Oncotarget internal or any external indexes or archives.

Meta-Analysis:

Prognostic role of anti-diabetic drugs in pancreatic cancer: A systematic review and meta-analysis

Lei Zheng, Shinan Yin _, Fenghua Yao, Hua Bai and Danqing Jing

 

Lei Zheng1,*, Shinan Yin1,*, Fenghua Yao2, Hua Bai1 and Danqing Jing1

1Department of Endocrinology, the First Affiliated Hospital of Chinese PLA General Hospital, Beijing, China

2Department of Nephrology, the First Hospital Affiliated to the Chinese PLA General Hospital, Beijing, China

*These authors contributed equally to this work

Correspondence to:

Shinan Yin, email: [email protected]

Keywords: anti-diabetic drug(ADD), metformin, pancreatic cancer, prognosis

Received: March 31, 2017     Accepted: April 27, 2017     Published: May 09, 2017


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17755